| ASSET | QUARTER | % RETURN |
|---|---|---|
QXO (QXO) | Q4 2023 | 416.92% |
Immunitybio (IBRX) | Q4 2023 | 195.29% |
Cytokinetics (CYTK) | Q4 2023 | 184.37% |
Scholar Rock (SRRK) | Q4 2023 | 166.67% |
CleanSpark (CLSK) | Q4 2023 | 164.73% |
Marathon Digital (MARA) | Q4 2023 | 155.33% |
TG Therapeutics (TGTX) | Q4 2023 | 102.13% |
Rhythm Pharmaceuticals (RYTM) | Q4 2023 | 100.57% |
Gap (GAP) | Q4 2023 | 98.92% |
Spirit Aerosystems (SPR) | Q4 2023 | 97.76% |
Edgewise Therapeutics (EWTX) | Q4 2023 | 90.92% |
Blueprint Medicines (BPMC) | Q4 2023 | 84.48% |
Kymera Therapeutics (KYMR) | Q4 2023 | 83.83% |
Twist Bioscience (TWST) | Q4 2023 | 83.57% |
Foot Locker (FL) | Q4 2023 | 83.03% |
Iris Energy (IREN) | Q4 2023 | 82.86% |
Compania de Minas Buenaventura SAA ADR (BVN) | Q4 2023 | 79.51% |
Central Puerto (CEPU) | Q4 2023 | 74.93% |
Macy’s (M) | Q4 2023 | 74.93% |
Harmony Gold Mining (HMY) | Q4 2023 | 73.8% |
Newmark (NMRK) | Q4 2023 | 71.11% |
Pactiv Evergreen (PTVE) | Q4 2023 | 70.54% |
StoneCo (STNE) | Q4 2023 | 69.77% |
Viking Therapeutics (VKTX) | Q4 2023 | 69.18% |
Terawulf (WULF) | Q4 2023 | 69.01% |
Mid-cap stocks are treated as having a market cap between $2B and $10B.
